Is a complete JANX research report available?

No complete published report is available for Janux Therapeutics, Inc. (JANX) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Janux Therapeutics, Inc. (JANX)

NASDAQ: JANX · USD

$15.6

+0.62 (+4.1%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first JANX analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	950.1M
Revenue (ttm)	13.7M
Net income (ttm)	-114.5M
EPS (ttm)	-$1.84
Shares out	61M
Volume	690,194
Beta	2.51
Price target	$37.2	+138.7%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 13.7M
Net income (ttm): -114.5M
EPS (ttm): -$1.84
Market cap: 950.1M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All JANX indicators

Market & fundamental data

Available fields

198

Groups with data

Currency

USD

Showing 198 of 198 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001817713
Company name	Janux Therapeutics, Inc.
Country	United States
Country code	US
Cusip	47103J105
Employees	108
Employees Change	-1%
Employees Change Percent	-0.92
Enterprise value	$15.3M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2021-06-11
Isin	US47103J1051
Last refreshed	2026-07-31
Market cap	$950.1M
Market cap category	Small-Cap
Price	$15.58
Price currency	USD
Rev Per Employee	127,157.41x
Sector	Healthcare
Sector PE	45.51
Sector PE Fwd	24.23
Sic	2834
Symbol	JANX
Website	https://www.januxrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-12.05%
EV Sales Forward	0.53x
EV/Sales	1.12x
FCF yield	-8.26%
P/B ratio	1.01x
P/S ratio	69.19x
PS Forward	33.11x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-1,143.11%
EBITDA Margin	-1,128.7%
Gross Profit	$-113.9M
Net Income	$-114.5M
Net Income Growth Years	0%
Pretax Margin	-833.6%
Profit Per Employee	$-1.1M
ROA	-9.44
Roa5y	-10.41
ROCE	-16.2
ROE	-11.72
Roe5y	-14.99
ROIC	-9.82

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-35.56%
Cagr3y	5.13%
Cagr5y	-13.01%
EPS Growth Years	0
Revenue Growth	47.1x
Revenue Growth Years	0x
Revenue Growth3 Y	14.83x
Revenue Growth5 Y	104.93x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.01
Assets	$1B
Cash	$956.4M
Current Assets	$1B
Current Liabilities	$58.9M
Debt	$21.6M
Debt Equity	$0.02
Equity	$941.5M
Liabilities	$86.7M
Long Term Assets	$26.2M
Long Term Liabilities	$27.8M
Net Cash	$934.8M
Net Cash By Market Cap	$98.39
Net Cash Growth	-5.72%
Net Debt Equity	$-0.99
Tangible Book Value	$941.5M
Tangible Book Value Per Share	$15.47
WACC	17.67

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	17.01
Net Working Capital	$-10.8M
Quick ratio	16.95
Working Capital	$943.1M
Working Capital Turnover	$0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-9.22%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-35.54%
200-day SMA	16.89
3Y total return	16.18%
50-day SMA	14.87
50-day SMA vs 200-day SMA	50under200
5Y total return	-50.18%
All Time High	71.71
All Time High Change	-78.27%
All Time High Date	2024-12-05
All Time Low	5.65
All Time Low Change	175.75%
All Time Low Date	2023-11-10
ATR	0.68
Beta	2.51
Beta1y	1.36
Beta2y	1.51
Ch YTD	12.9
High	15.7
High52	35.34
High52 Date	2025-11-26
High52ch	-55.91%
Low	14.79
Low52	12.12
Low52 Date	2026-02-05
Low52ch	28.55%
Ma50ch	4.8%
Price vs 200-day SMA	-7.77%
RSI	51.8
RSI Monthly	42.6
RSI Weekly	48.76
Sharpe ratio	-0.16x
Sortino ratio	-0.13
Total Return	-9.22%
Tr YTD	12.9
Tr1m	1.66%
Tr1w	-0.89%
Tr3m	10.42%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	18
Analyst Count Top	11
Analyst Price Target Top	$42.6
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.28
Earnings Revenue Estimate	21,771,768x
Operating Income	$-157M
Operating margin	-1,143.1
Price target	$37.19
Price Target Change	$139
Price Target Change Top	$173

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	39,126,262%
Float Percent	64.16%
Shares Insiders	6.64%
Shares Institutions	71.01%
Shares Out	60,984,354
Shares Qo Q	0.84%
Shares Yo Y	9.22%
Short Float	16.5%
Short Ratio	4.4
Short Shares	10.58

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-117.3M
Adjusted OCF	-116,336,000
Average Volume	865,101.55x
Bv Per Share	15.47
CAPEX	$-945,000
Ch1m	1.66
Ch1w	-0.89
Ch1y	-35.54
Ch3m	10.42
Ch3y	16.18
Ch5y	-50.18
Ch6m	12.65
Change	4.14%
Change From Open	4.7
Close	14.96
Days Gap	-0.53
Depreciation Amortization	1,979,000
Dollar Volume	10,753,222.5
Earnings Date	2026-08-07
Earnings Time	amc
EBIT	$-157M
EBITDA	$-155M
EPS	$-1.84
F Score	2
FCF	$-78.5M
FCF EV Yield	-512.32x
FCF Per Share	$-1.29
Financing CF	7,936,000
Fiscal Year End	December
Founded	2,017
Investing CF	47,697,000
Ipr	-8.35
Iprfo	-54.18
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Ma150	14.34
Ma150ch	8.66%
Ma20	15.85
Ma20ch	-1.72%
Net CF	-21,915,000
Next Earnings Date	2026-08-10
Open	14.88
Optionable	Yes
Position In Range	86.81
Ppne	21,416,000
Price Date	2026-07-30
Ptbv Ratio	1.01
Relative Volume	0.8x
Revenue	13,733,000x
SBC By Revenue	282.44x
Share Based Comp	38,788,000
Tr6m	12.65%
Us State	California
Volume	690,194
Z Score	9.22

Janux Therapeutics, Inc. (JANX)

Coverage state: Market snapshot only — no published research

Generate the first JANX analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · JANX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All JANX indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on JANX

Frequently asked questions